{
    "clinical_study": {
        "@rank": "33626", 
        "acronym": "RECOVERY", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo for methotrexate"
            }, 
            {
                "arm_group_label": "Methotrexate", 
                "arm_group_type": "Experimental", 
                "description": "Methotrexate 10 mg once a week orally"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the this study is to evaluate the effectiveness of methotrexate added to\n      treatment as usual on positive and negative symptoms, cognitive and social functioning and\n      quality of life  of patients suffering from schizophrenia."
        }, 
        "brief_title": "RCT of Methotrexate Added to Treatment As Usual in Schizophrenia", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Schizophrenia", 
            "Schizoaffective Disorder", 
            "Schizophreniform Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Psychotic Disorders", 
                "Schizophrenia"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of the study is to test the prediction that addition of methotrexate to\n      treatment as usual (TAU) for patients with schizophrenia will result in following outcomes:\n\n        -  Primary:\n\n             -  improvement in negative symptoms\n\n             -  improvement in positive symptoms\n\n        -  Secondary:\n\n             -  improvement in social functioning\n\n             -  improvement in cognitive functions\n\n             -  acceptability and tolerability of methotrexate added to TAU A total 72\n                participants (36 participants in intervention group and 36 in control group)\n                meeting inclusion criteria of the study will be recruited and randomized in study\n                in two arms. Research assistants and participating psychiatrists will assess\n                participants for eligibility criteria. After providing detailed information\n                regarding study by using patient information sheet, written informed consent will\n                be taken from participants. Trained research assistant will asses participants at\n                baseline, 2, 4, 6 and 12 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent, indicating that the subject understood the purpose of and\n             procedures required for the study, before the initiation of any study specific\n             procedures\n\n          -  Aged 18 to 35 years\n\n          -  Diagnostic and Statistical Manual-IV (DSM-IV) diagnosed first episode psychosis,\n             schizophrenia, schizoaffective disorder, psychosis not otherwise specified or\n             schizophreniform disorder.\n\n          -  First episode (within first 5 years of diagnosis)\n\n          -  Competent and willing to give informed consent\n\n          -  Medication remained stable 4 weeks prior to baseline.\n\n          -  Able to take oral medication and likely to complete the required evaluations.\n\n          -  Female participants of child bearing capability must be willing to use adequate\n             contraceptives for the duration of the study, and, willing to have a pregnancy test\n             pre treatment and at ten weekly intervals while on study medication.\n\n               1. Adequate contraception is defined as use of contraceptive double barrier system\n                  (i.e. condom and spermicide) or contraceptive implant, oral contraceptive or\n                  injected depot contraceptive plus other form of contraceptive i.e. condom.\n                  Females will be considered incapable of child bearing if they are one year\n                  post-menopausal or irreversibly surgically sterilised.\n\n        Exclusion Criteria:\n\n          -  Violation of any inclusion criteria\n\n          -  Failure to perform screening or baseline examinations\n\n          -  Relevant ICD 10 organic brain disease or neurological diagnoses\n\n          -  Patients with liver disease\n\n          -  Patients who will meet the criteria for a DSM-IV TR diagnosis of alcohol or substance\n             abuse (other than for nicotine) within the last month or the criteria for DSM-IV TR\n             alcohol or substance dependence (other than for nicotine) within the last 6 months\n\n          -  Any change of psychotropic medications within the previous 4 weeks\n\n          -  Recreational drugs or alcohol abuse\n\n          -  Pregnant or lactating women and those of reproductive age without adequate\n             contraception\n\n          -  Relevant medical illness will be determined in the first instance by asking the\n             patients mental health care team if the patient has any medical condition/problems.\n             After consent has been obtained the research nurse/ research doctor will then have\n             access to the patients' notes and will assess patient eligibility to take part in the\n             clinical trial by scrutinising the patients' past medical history, most recent blood\n             results, electrocardiograms, as well as any physical tests that have been performed\n             on the patient."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074319", 
            "org_study_id": "RECOVERY-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Placebo", 
                "Methotrexate"
            ], 
            "description": "Treatment as usual or standard treatment for psychosis will be common in all arms", 
            "intervention_name": "TAU", 
            "intervention_type": "Drug", 
            "other_name": "TAU or Treatment As Usual"
        }, 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Schizophrenia", 
            "Anti-Inflammatory", 
            "Methotrexate", 
            "Psychosis Not Otherwise Specified"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "link": {
            "description": "Website of Pakistan Institute of Learning and Living", 
            "url": "http://pill.org.pk"
        }, 
        "location": [
            {
                "contact": {
                    "email": "razaur@yahoo.com", 
                    "last_name": "Prof Raza U Rahman, FCPS", 
                    "phone": "00-92-21-9215740-50", 
                    "phone_ext": "2500"
                }, 
                "facility": {
                    "address": {
                        "city": "Karachi", 
                        "country": "Pakistan", 
                        "state": "Sindh", 
                        "zip": "72000"
                    }, 
                    "name": "Civil hospital Karachi"
                }, 
                "investigator": {
                    "last_name": "Prof Raza U Rahman, FCPS", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mmham@yahoo.com", 
                    "last_name": "Prof Munir Hamarani, FCPS", 
                    "phone": "00923009272002"
                }, 
                "facility": {
                    "address": {
                        "city": "Karachi", 
                        "country": "Pakistan", 
                        "state": "Sindh", 
                        "zip": "72000"
                    }, 
                    "name": "Abasi Shaheed Hospital"
                }, 
                "investigator": {
                    "last_name": "Prof Munir Hamarani, FCPS", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kazmiajmal@yahoo.com", 
                    "last_name": "Dr Ajmal Kazmi, MRCPsych", 
                    "phone": "00923213783890"
                }, 
                "facility": {
                    "address": {
                        "city": "Karachi", 
                        "country": "Pakistan", 
                        "state": "Sindh", 
                        "zip": "72000"
                    }, 
                    "name": "Karwn e Hayat"
                }, 
                "investigator": {
                    "last_name": "Dr Ajmal Kazmi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kazmiajmal@yahoo.com", 
                    "last_name": "Dr Ajmal Kazmi", 
                    "phone": "00923213783890"
                }, 
                "facility": {
                    "address": {
                        "city": "Karachi", 
                        "country": "Pakistan", 
                        "state": "Sindh", 
                        "zip": "72000"
                    }, 
                    "name": "Institute of Behavioural Sciences"
                }, 
                "investigator": {
                    "last_name": "Dr Ajmal Kazmi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Pakistan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised Double Blind Placebo Controlled 12 Week Trial of Methotrexate Added to Treatment As Usual in Early Schizophrenia", 
        "other_outcome": {
            "description": "Self-rating questionnaire assessing social functioning in 7 domains.", 
            "measure": "Social Functioning Scale", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "overall_contact": {
            "email": "imran.chaudhry@manchester.ac.uk", 
            "last_name": "Prof Imran B Chaudhry, MD", 
            "phone": "0441254226392"
        }, 
        "overall_contact_backup": {
            "email": "nusrat.husain@manchester.ac.uk", 
            "last_name": "Dr Nusrat Husain, MD", 
            "phone": "0441254226392"
        }, 
        "overall_official": {
            "affiliation": "University of Manchester", 
            "last_name": "Prof Imran B Chaudhry, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Dow University of Health Sciences: Pakistan", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PANSS is an assessment measures to assess severity of symptoms of schizophrenia", 
            "measure": "Positive and Negative Syndrome Scale PANSS", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "reference": [
            {
                "PMID": "19091984", 
                "citation": "Behrens MM, Ali SS, Dugan LL. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci. 2008 Dec 17;28(51):13957-66."
            }, 
            {
                "PMID": "19589054", 
                "citation": "Bernstein HG, Steiner J, Bogerts B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother. 2009 Jul;9(7):1059-71. doi: 10.1586/ern.09.59. Review."
            }, 
            {
                "PMID": "15914465", 
                "citation": "Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005 Jun;57(2):163-72. Review."
            }, 
            {
                "citation": "Doorduin, J., de Vries, E.F., Willemsen, A.T., de Groot, J.C., Dierckx, R.A., Klein, H.C. Neuroin\ufb02ammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med 2009; 50, 1801-1807."
            }, 
            {
                "PMID": "16580814", 
                "citation": "Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun. 2006 Nov;20(6):532-45. Epub 2006 Apr 3. Review."
            }, 
            {
                "PMID": "1974941", 
                "citation": "Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, Chanarin I, Reynolds EH. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990 Aug 18;336(8712):392-5."
            }, 
            {
                "PMID": "16368293", 
                "citation": "Gong K, Zhang Z, Sun X, Zhang X, Li A, Yan J, Luo Q, Gao Y, Feng Y. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. Am Heart J. 2006 Jan;151(1):62-8."
            }, 
            {
                "PMID": "15639649", 
                "citation": "Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005 Feb;114(2):154-63."
            }, 
            {
                "PMID": "19579286", 
                "citation": "Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009 Jun;63(3):257-65. Review."
            }, 
            {
                "PMID": "7978695", 
                "citation": "Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL, Alarc\u00f3n GS. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994 Dec 1;121(11):833-41."
            }, 
            {
                "PMID": "18005941", 
                "citation": "Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008 Apr 15;63(8):801-8. Epub 2007 Nov 19."
            }, 
            {
                "PMID": "1773245", 
                "citation": "Procter A. Enhancement of recovery from psychiatric illness by methylfolate. Br J Psychiatry. 1991 Aug;159:271-2."
            }, 
            {
                "PMID": "12359872", 
                "citation": "Rajagopalan PT, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammes GG. Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13481-6. Epub 2002 Oct 1."
            }, 
            {
                "PMID": "15710474", 
                "citation": "Schulte-Herbr\u00fcggen O, Nassenstein C, Lommatzsch M, Quarcoo D, Renz H, Braun A. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J Neuroimmunol. 2005 Mar;160(1-2):204-9. Epub 2004 Dec 22."
            }, 
            {
                "PMID": "18534557", 
                "citation": "van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, Luurtsema G, Windhorst AD, Cahn W, Lammertsma AA, Kahn RS. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008 Nov 1;64(9):820-2. doi: 10.1016/j.biopsych.2008.04.025. Epub 2008 Jun 4."
            }, 
            {
                "PMID": "14963199", 
                "citation": "Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004 Mar;43(3):267-71. Epub 2004 Jan 6. Review."
            }, 
            {
                "PMID": "19884981", 
                "citation": "Zhang Z, Zhao P, Li A, Lv X, Gao Y, Sun H, Ding Y, Liu J. Effects of methotrexate on plasma cytokines and cardiac remodeling and function in postmyocarditis rats. Mediators Inflamm. 2009;2009:389720. doi: 10.1155/2009/389720. Epub 2009 Oct 26."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074319"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Measuring all seven domains recommended by MATRICS (NIMH initiative). These domains include speed processing, attention/vigilance, Working memory (nonverbal & verbal), verbal learning, visual learning, reasoning and problem solving and social cognitions.", 
            "measure": "CogState", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "Pakistan Institute of Learning and Living", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Pakistan Institute of Learning and Living, Karachi, Pakistan", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Abassi Shaheed Hospital, Karachi, Pakistan", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Dow University of Health Sciences", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Karwan e Hayat, Karachi, Pakistan", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Institute of Behavioural Sciences, Karachi, Pakistan", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Pakistan Institute of Learning and Living", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}